Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

ABSTRACT:

Background

The current standard of care for patients with high-grade gliomas includes surgical resection, chemotherapy, and radiation; but even still most patients experience disease progression and succumb to their illness within a few years of diagnosis. Immunotherapy, which stimulates an anti-tumor immune response, has been revolutionary in the treatment of some hematologic and solid malignancies, generating substantial excitement for its potential for patients with glioblastoma. However, to date, the preclinical success of these approaches against high-grade glioma models has not been replicated in human clinical trials. Moreover, the complex response to these biologically active treatments can complicate management decisions, and the neurosurgical oncology community needs to b

SUBMITTER: Young JS 

PROVIDER: S-EPMC6642850 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature